

# DERMATOLOGY ORDER SET P: 877.365.5566 | F: 855.889.2946

A Carelon Company

## Fax completed form, insurance information, and clinical documentation to 855.889.2946

Phone: \_

Patient Name:

DOB:

Patient Status: 🗆 New to Therapy

□ Continuing Therapy **Nex** 

**Next Treatment Date:** 

#### **MEDICAL INFORMATION**

**PATIENT INFORMATION:** 

Patient Weight: \_\_\_\_\_ lbs. (required) Allergies: \_

THERAPTORDER			
Diagnosis	Medication Orders	Refills	
Dermatomyositis     Polymyositis     Pemphigoid/Pemphigus     Other:	IVIg Orders: mg/kg OR gm/kg IV x day(s) OR divided over day(s)         Frequency: Every weeks OR         Preferred brand: (Paragon to choose if not indicated)	🗆 x1 year	
ICD-10:	Additional Ig orders:		
□ CIU ICD-10:	□ Xolair □ 150mg SQ every 4 weeks □ 300mg SQ every 4 weeks Note: Patient must have an EpiPen in their possession on their appointment date		
□ Pemphigus Vulgaris ICD-10:	□ Rituximab or rituximab biosimilar as required by patient's insurance         □ Do not substitute. Infuse the following rituximab product:         For Paragon use only. Brand:         Initial Dose:       1000mg IV at day 0, 15 days         Maintenance Dose:       500mg IV at month 12 and every 6 months thereafter         Other dose:		
	□ Infliximab or infliximab biosimilar as required by patient's insurance □ Do not substitute. Infuse the following infliximab product: For Paragon use only. Brand: Dose: mg/kg Frequency: □ Every weeks OR □ 0, 2, 6 then every 8 weeks		
□ Psoriatic Arthritis □ Psoriasis □ Plaque Psoriasis ICD-10:	Simponi Aria       Initial Dose: □ 2mg/kg IV at weeks 0, 4 and then every 8 weeks         Maintenance Dose: □ 2mg/kg IV every 8 weeks         Stelara       45mg SQ initially and 4 weeks later followed by 45mg every 12 weeks (≤ 100kg)         □ 90mg SQ initially and 4 weeks later followed by 90mg every 12 weeks (>100kg)         Maintenance Dose: □ 45mg SQ every 12 weeks	□ x1 year	
	<ul> <li>Ilumya Initial Dose:          <ul> <li>100mg SQ at weeks 0, 4 and every 12 weeks thereafter Maintenance Dose:              <li>100mg SQ every 12 weeks</li> </li></ul> </li> <li>Cimzia 200mg SQ every 2 weeks          <ul> <li>400mg SQ every 2 weeks</li> <li>400mg SQ at weeks 0, 2, and 4 followed by 200mg 400mg every 2 weeks</li> </ul> </li> </ul>		
Generalized Pustular Psoriasis	□ Spevigo 900mg IV x 1		
ICD-10:	□ Repeat Spevigo 900mg IV in 1 week if symptoms persist		
Premedication orders:       Tylenol □ 1000mg □ 500mg PO, please choose one antihistamine:         □ Diphenhydramine 25mg PO □ Loratadine 10mg PO □ Cetirizine 10mg PO □ Quzyttir 10mg IVP         Additional premedications:       □ Solu-Medrol mg IVP □ Solu-Cortef mg IVP □ Other         Lab orders:       Frequency:       □ Every infusion □ Other:         □ Yearly TB QFT       □ Baseline HepBcAB total       Required labs to be drawn by:       □ Paragon □ Referring provider			
<b>PROVIDER INFOR</b>	MATION		
agent in dealing with medical and pres	ervices, you are authorizing <i>Paragon Healthcare, Inc.</i> and its employees to serve as your prior authorization and specialty pharmac cription insurance companies, and to select the preferred site of care for the patient. Signature: Date: Phone: Fax: Contact Person: selecting site of care (if checked, please list site of care):	-	
PREFERRED LOCA			
City:	State: View our locations here:		
PARAGONHEALTHCARE.COM IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under			

applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.



PHI-REF-ORD-10028-V7



# COMPREHENSIVE SUPPORT FOR DERMATOLOGY THERAPY

A Carelon Company

#### PATIENT INFORMATION:

Patient Name:	DOB:
<b>REQUIRED DOCUMENTATION FOR REFERRAL PR</b>	OCESSING & INSURANCE APPROVAL
□ Include <u>signed</u> and <u>completed</u> order (MD/prescr	iber to complete page 1)
□ Include patient demographic information and ins	surance information
Include patient's medication list	
Supporting clinical notes to include any past trie benefits, or contraindications to conventional the	-
For biologic orders, has the patient had a doc or failed trial of a conventional therapy (i.e., s If yes, which drug(s)?	-
For biologic orders, does the patient have a c trial to any other biologic (i.e., Stelara, Cimzia If yes, which drug(s)?	)? □ Yes □ No
□ Include labs and/or test results to support diagn	osis
☐ <i>If applicable</i> - Last known biological therapy: If patient is switching to biological therapy: upperiod of weeks prior to starting to starti	gic therapies, please perform a wash-
Other medical necessity:	
REQUIRED PRE-SCREENING (BASED ON DRUG TH	IERAPY)
<ul> <li>TB screening test completed within 12 months</li> <li>Required for: Cimzia, infliximab, Stelara, Ilumya,</li> <li>Positive          Negative     </li> </ul>	
<ul> <li>Hepatitis B screening (Hepatitis B surface antig Required for: Cimzia, infliximab, rituximab, Simponi Aria</li> <li>Hepatitis B core antibody total (not IgM) -          <ul> <li>Po Required for: rituximab</li> </ul> </li> </ul>	
Serum immunoglobulins - attach results Recomm	mended for: rituximab
Baseline creatinine Required for: IVIG *If TB or Hepatitis B results are positive - please provide documentation of t	reatment or medical clearance, and a negative CXR (TB+)

Paragon Healthcare will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

## Please fax all information to (855) 889-2946 or call (877) 365-5566 for assistance

PARAGONHEALTHCARE.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.